The Radiation Therapy Oncology Group (RTOG) is the leading multicenter and multidisciplinary research organization systematically testing novel radiotherapy (RT) approaches against cancer and pursuing fully integrated translational research to enhance this effort. The group will build on its outstanding scientific accomplishments in the current funding period to conduct research based on three fundamental initiatives: 1. Physical Targeting: RTOG will implement and test advances in imaging and high-precision RT planning and delivery technologies in clinical trials. 2. Molecular Targeting: Combined with RT: RTOG will design and conduct hypothesis-driven trials testing the integration of novel molecular targeted anti-cancer agents with optimized RT or chemo-RT. 3. Translational Research: RTOG will implement powerful biostatistical and medical informatics approaches to its unique and inter-linked clinical, biophysical, biologic, and outcomes databases that will faciliate hypothesis-driven analyses of these resources. The RTOG's research is primarily directed toward patients with brain tumors, head and neck cancer, lung cancer, gastrointestinal cancer, and genitourinal cancer. More limited research strategies have been developed for patients with gynecologic and breast cancer and sarcoma. RTOG research is supported by outstanding contributions from the Advanced Technology Integration, the Translational Research Program, and the Health Services Research and Outcomes Committees as well as the newly relocated Biospecimen Resource and from the four core committees of Medical Oncology, Medical Physics, Pathology, and Surgical Oncology. These contributions are well coordinated by a strong administrative and scientific infrastructure and have resulted in increased productivity in the current as compared with the prior funding cycle in terms of: 1. publication record; 2. clinical trials activated and completed; 3. overall patient accrual; 4. public and private funding of group research; 5. collaboration with other cooperative groups and other NIH-funded organizations;and 6. increased participation and leadership of Canadian investigators, with 8 of 37 full member institutions being Canadian. Close to two-thirds of all cancer patients receive radiation therapy for cure or for symptom relief. Novel technology, molecular targeted drugs and advances in radiation and cancer biology will improve the success rate of radiation therapy through clinical research over the next six years.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
American College of Radiology
United States
Zip Code
Voog, Justin C; Paulus, Rebecca; Shipley, William U et al. (2016) Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08. Eur Urol 69:204-10
Lustberg, Tim; Bailey, Michael; Thwaites, David I et al. (2016) Implementation of a rapid learning platform: Predicting 2-year survival in laryngeal carcinoma patients in a clinical setting. Oncotarget :
White, Julia; Winter, Kathryn; Kuske, Robert R et al. (2016) Long-Term Cancer Outcomes From Study NRG Oncology/RTOG 9517: A Phase 2 Study of Accelerated Partial Breast Irradiation With Multicatheter Brachytherapy After Lumpectomy for Early-Stage Breast Cancer. Int J Radiat Oncol Biol Phys 95:1460-5
Divi, Vasu; Harris, Jonathan; Harari, Paul M et al. (2016) Establishing quality indicators for neck dissection: Correlating the number of lymph nodes with oncologic outcomes (NRG Oncology RTOG 9501 and RTOG 0234). Cancer :
Small Jr, William; James, Jennifer L; Moore, Timothy D et al. (2016) Utility of the ACE Inhibitor Captopril in Mitigating Radiation-associated Pulmonary Toxicity in Lung Cancer: Results From NRG Oncology RTOG 0123. Am J Clin Oncol :
Ohri, Nitin; Duan, Fenghai; Snyder, Bradley S et al. (2016) Pretreatment 18F-FDG PET Textural Features in Locally Advanced Non-Small Cell Lung Cancer: Secondary Analysis of ACRIN 6668/RTOG 0235. J Nucl Med 57:842-8
Buckner, Jan C; Shaw, Edward G; Pugh, Stephanie L et al. (2016) Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N Engl J Med 374:1344-55
Mitin, Timur; George, Asha; Zietman, Anthony L et al. (2016) Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233. Int J Radiat Oncol Biol Phys 94:67-74
Mak, Raymond H; Hunt, Daniel; Efstathiou, Jason A et al. (2016) Acute and late urinary toxicity following radiation in men with an intact prostate gland or after a radical prostatectomy: A secondary analysis of RTOG 94-08 and 96-01. Urol Oncol 34:430.e1-7
Rogers, C Leland; Perry, Arie; Pugh, Stephanie et al. (2016) Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539. Neuro Oncol 18:565-74

Showing the most recent 10 out of 539 publications